From novel drug therapies to cutting-edge medical technologies, JLABS Singapore, Johnson & Johnson’s flagship incubator for early-stage companies, is accelerating healthcare innovation from Singapore’s world-class #BioTech ecosystem.
Since its launch a year ago, JLABS Singapore has incubated 35 innovative life sciences companies across areas like #MedTech, BioTech and digital health. They include:
?? Avecris, a spin-out from the National University of Singapore which specialises in gene therapy for rare diseases: It became the first company in Asia to join the J&J-BARDA BLUE KNIGHT ? programme, a joint initiative between J&J Innovation and the US Biomedical Advanced Research and Development Authority that aims to accelerate innovation in health security and response.
?? Respiree, an A*STAR - Agency for Science, Technology and Research spin-out: After graduating from JLABS Singapore, the company was able to expand to JLABS South San Francisco to be closer to the US market for its next phase of growth.
?? VerImmune, which focuses on advancing novel cancer immunotherapy: Its partnership with A*STAR’s Bioprocessing Technology Institute was facilitated with the support of JLABS Singapore.
JLABS Singapore offers local and regional startups access to a world-class network of investors and corporate partners, as well as resources and industry know-how to translate early-stage discoveries into commercially viable products and solutions. To boost the fundraising efforts of early-stage startups, the incubator has also introduced an agreement with BioMedTech incubator co11ab and expanded its Investor Hub to better connect companies with global, regional and local investors.
Home to over 300 BioTech and MedTech startups, and a growing community of biomedical players with more than 60 manufacturing plants here, Singapore is well-positioned to partner companies in solving tough health challenges and driving scientific breakthroughs. Learn more about the JLABS initiative here: https://lnkd.in/g5RCZMWq
